IHH: Strategic Expansion Underpins Growth Outlook
| Investment Bank | TA SECURITIES |
|---|---|
| TP (Target Price) | RM0.25 (+25.0%) |
| Last Traded | RM0.20 |
| Recommendation |
A leading healthcare provider has announced a significant extension of its bed expansion plan, aiming to add 4,000 beds by 2030, an acceleration from the previous 2028 target. This strategic pivot emphasizes higher-acuity services and increased daycare procedures, signaling a robust long-term growth trajectory.
Performance Review
Inpatient admissions at key facilities like Mount Elizabeth Hospital showed strength, particularly in December 2025 and January 2026. While a temporary dip is anticipated in February-March 2026 due to seasonal factors, the overall momentum remains positive. Operations in Turkey and Europe also contributed to an improved average bed occupancy rate, surpassing 50% in the first quarter of 2024. The group is proactively managing operational energies to ensure healthy medium- to long-term margins.
Despite varying utilization rates, the company has demonstrated resilience, maintaining robust financial performance. Management’s proactive cost management and strategic energy deployment are aimed at ensuring mid-20s margins in the medium to long term, with sustainable profit growth.
Future Outlook
The outlook remains positive, driven by the extended bed expansion, rising patient volumes, and persistent demand for elective medical procedures. The expanded capacity is expected to contribute to a 25% revenue increase over the next 5-7 years, significantly boosting both top-line growth and free cash flow. A strong focus on medical tourism, particularly from Singapore, is also expected to further bolster revenue and improve margins.
Challenges and Risks
However, the company acknowledges potential challenges, including softer utilization rates in certain segments and rising competition from private hospital peers. Regulatory changes also present a downside risk to the otherwise strong growth projections.
Analyst View
A prominent investment bank, PhillipCapital, maintains a “BUY” recommendation on the company, reaffirming its confidence in the long-term growth prospects. The bank reiterates an unchanged SOP-derived 12-month target price of RM10.27, underpinned by expectations of continued growth momentum and strong operational execution.
